DHX58 and lung adenocarcinoma: We previously reported that the RLR agonist Poly(I:C)-HMW/LyoVecTM (Poly(I:C)) enhanced radiosensitivity and that cotreatment with Poly(I:C) and ionizing radiation (IR) more than additively increased cell death in lung adenocarcinoma cells, indicating that Poly(I:C) modulates the cellular radiation response.